Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Humanistic burden and health-related quality of life
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Disease description Burden of Neovascular age-related macular degeneration

Humanistic burden and health-related quality of life

4 evidence topics · 2 sources

Treatment-day time burden

“The majority of patients reported to spend 1–3 hours (43.1%), followed by 4–6 hours (30.8%)” (opens the source at this quote in a new tab)

Emotional burden of injection visits

“Patients reported that they were nervous or struggled to sleep prior to treatment” (opens the source at this quote in a new tab)
“33.1% of patients reported to be stressed and 15.4% struggled to sleep” (opens the source at this quote in a new tab)
“The majority of patients reported the treatment as uncomfortable (54.6%) or as somewhat painful (26.2%)” (opens the source at this quote in a new tab)

Caregiver involvement in treatment visits

“Approximately half of the patients required caregiver support every visit (37.7%) or occasionally (14.6%)” (opens the source at this quote in a new tab)

Falls-related concern and quality of life

“Concern about falling is another common issue for older people, with far-reaching implications including activity restriction, reduced quality of life” (opens the source at this quote in a new tab)